Interleukin-6 (IL-6) is a protein that in humans is encoded by the "IL6" gene. IL-6 is an interleukin that acts as both a pro-inflammatory and anti-inflammatory cytokine. It is secreted by T cells and macrophages to stimulate immune response to trauma, especially burns or other tissue damage leading to inflammation.
When the pro-inflammatory pair, a receptor called CCR2 and its ligand CCL-2, get together, it increases the risk of developing type 1 diabetes, scientists report.
Neuroinflammatory diseases, including Alzheimer's disease and traumatic brain injury, have been linked to deposits of a tough protein known as fibrin, derived from the blood clotting factor fibrinogen.
For the first time, scientists have successfully used gene therapy to make mice walk again after these animals suffered a complete cross-sectional injury.
Systemic sclerosis is an autoimmune disease associated with inflammation and fibrosis, or scarring, that affects organs including the skin, heart, kidney and lungs.
Gomila et al. recently uploaded a study to the preprint server medRxiv* (November 2020), aiming to utilize MALDI-TOF MS to analyze the sera of patients infected with SARS-CoV-2 in a range of disease severity states.
A number of vaccines contain ingredients known as adjuvants that make them more effective by triggering a more powerful immune response.
Normal brain development requires a precise interplay between neuronal and non-neuronal (also called glial) cells. In a new study, researchers from the University of Tsukuba revealed how the loss of protein arginine methyltransferase (PRMT) 1 causes disruptions in glial cells and affects proper brain development.
A major percentage of COVID-19 cases have become so severe that hospital admissions have become mandatory for both monitoring and treatment.
Critically ill COVID-19 patients who received a single dose of a drug that calms an overreacting immune system were 45% less likely to die overall, and more likely to be out of the hospital or off a ventilator one month after treatment, compared with those who didn't receive the drug, according to a new study by a team from the University of Michigan.
More than a decade before people with Huntington's disease show symptoms, they can exhibit abnormally high levels of an immune-system molecule called interleukin-6 (IL-6), which has led many researchers to suspect IL-6 of promoting the eventual neurological devastation associated with the genetic condition.